Alzheimer's drug Leqembi gets full FDA approval. Medicare coverage will likely follow (npr.org)
The Food and Drug Administration has fully approved Leqembi, the first drug shown to slow down Alzheimer's disease. Andrew Harnik/AP To read more of Jon Hamilton's article, please click here. The Food and Drug Administration has fully approved the first drug shown to slow down Alzheimer's disease. The action means that Leqembi, whose generic name is lecanemab, should be widely covered by the federal Medicare health insurance program, which primarily serves adults age 65 and older. So more...